Dynamic photo-therapy uses a photosynthesizing substance that is applied to the skin for a few hours
before his exposure to a specific light.
Dynamic photo-therapy uses a photosynthesizing substance (causing a tissue
susceptibility to some lights) that is applied on the skin for a few
hours before his exposure to a specific light (light blue or red).
The
substance is applied to the skin as a liquid or cream that contains
(5-ALA-HCL) aminolevulinic acid and the methyl aminolevulinate (MAL). These photo-sensitizers is specifically absorbed by the diseased tissues, and sebaceous glands.
The Red or blue light exposure is achieved with a special lamp that active substance that has penetrated the tissues. Activation of photosynthesizing substance causes the specific destruction of tissues which have absorbed it.
The
Galderma laboratory markets Metvixia cream France, its use is
indicated for the treatment of Actinic Keratoses (precancerous
Keratoses), superficial basal cell carcinomas face and the Bowen disease
(Intraepidermal squamous cell carcinoma). Metvixia cream is applied to the area was treated for three hours before lighting lights LED red (Aktilite). Metvixia treatment protocol is detailed on a separate sheet. Metvixia ® is available now in France. The
essential interest of dynamic phototherapy with Metvixia (MAL - PDT)
is the treatment of cancer of the skin, it allows eliminating virtually
without scar of precancerous lesions of the skin and certain cancers. This technique also allows to simultaneously process several lesions. One or several treatments may be necessary.
The
DUSA laboratory markets the Levulan Kerastic in the United States and
the Canada, it is a liquid applied to the area to treat for 12 to 16
hours before its activation by light blue (BLU - U). Dynamic
phototherapy with 5 - ALA (ALA - PDT) is also used to destroy Keratoses
Actinic but also in the treatment of acne and the field of aesthetics
(treatment of brown spots and wrinkles). Levulan kerastick is not indicated for the treatment of skin cancer.
No comments:
Post a Comment